Acadia Pharmaceuticals ACAD Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Acadia Pharmaceuticals (ACAD) reported accretion (amortization) of discounts and premiums, investments of $453K in Q1 2026.
- How has Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 78.6% year-over-year, from $2.12M to $453K.
- What is the long-term trend for Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 22.6% compound annual growth rate (CAGR), from -$2.4M to $5.42M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income for the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the gradual adjustment of the carrying value of investment securities toward their face value over time. Investors use this to reconcile reported net income with actual cash flows generated from investment portfolios.